

Middle East & Africa Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)

Market Report | 2022-10-07 | 116 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The influenza vaccines market in Middle East & Africa is expected to grow from US\$ 374.35 million in 2022 to US\$ 533.85 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028.

Strong Pipeline Candidates for Influenza Vaccines

Leading players in the influenza vaccines market have multiple projects on drug delivery and biological pipelines based on proprietary technology. The most advanced candidate population in drug delivery completed 2 Phase I studies. The pipeline also includes a large number of compounds that have completed preclinical evaluation. Pipeline candidates are focused on unlocking the science of the immune system, human genetics, and cutting-edge technologies to develop innovative vaccines. Companies are investing in scientific and technical excellence to develop and introduce new vaccines and specific drugs against infectious diseases, including influenza. Vaccines and viral therapeutic candidates in the pipeline are capable of rapidly and specifically responding to the most pressing health threats.

Market Overview

The Middle East & Africa Influenza Vaccines Market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of the

Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Middle East & Africa. In 2021, South Africa was the largest market for Influenza Market in the region. The market for Influenza Market in the Middle East & Africa is anticipated to grow at a CAGR of 6.1% during the forecast period The influenza vaccines market is expected to grow due to the huge population base, increasing cases of influenza, and growing research studies across the region. Moreover, growing healthcare facilities help propel the market growth. Saudi Arabia is one of the important countries in the Middle Eastern region that has significant scope for the influenza vaccines market. The healthcare system in the country is developing at a rapid pace as well as increasing number of international companies are developing medical and research teams in the country. A sharp increase in the state health budget is also expected to drive the growth of the influenza vaccines market in the country.

Saudi Arabia is among the fastest growing regions in the Middle East & Africa whose growth is driven by a huge population base with chronic diseases. According to the latest WHO data published in 2020 Influenza and Pneumonia Deaths in Saudi Arabia reached 6,132 or 4.58% of total deaths. The age-adjusted Death Rate is 30.87 per 100,000 of population ranks Saudi Arabia 82 in the world. In 2009, in response to the pandemic Influenza A(H1N1)pdm09, the public health department at the Ministry of Health in Saudi Arabia established its first case-based Influenza surveillance system. In Saudi Arabia, rising healthcare spending and well-established hospital and tertiary care centers fuel the growth of the market. The government has increased healthcare and social affairs expenditure by 48% to US\$ 42.64 billion (SR160bn) for the development of new healthcare centers, hospitals, and primary care centers. Thus, such initiatives by the government, and penetration of international market players are expected to drive the growth of influenza vaccines market in Saudi Arabia.

Middle East & Africa Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Million)

Middle East & Africa Influenza Vaccines Market Segmentation

The Middle East & Africa Influenza Vaccines Market is segmented into vaccine type, virus type, technology, route of administration, and country.

Based on vaccine type, the Middle East & Africa influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.

Based on virus type, the Middle East & Africa influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.

Based on technology, the Middle East & Africa influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.

Based on route of administration, the Middle East & Africa influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.

Based on country, the market is segmented into the UAE, Saudi Arabia, South Africa, and the rest of Middle East & Africa. Saudi Arabia dominated the market share in 2022.

AstraZeneca; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Middle East & Africa.

Table of Contents:

TABLE OF CONTENTS

Scotts International. EU Vat number: PL 6772247784

- 1. Introduction
- 1.1 Study Scope
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 MEA Influenza Vaccines Market By Vaccine Type
- 1.3.2 MEA Influenza Vaccines Market By Virus Type
- 1.3.3 MEA Influenza Vaccines Market By Technology
- 1.3.4 MEA Influenza Vaccines Market By Route Of Administration
- 1.3.5 MEA Influenza Vaccines Market By Country
- 2. MEA Influenza Vaccines Market Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. MEA Influenza Vaccines Market Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 MEA PEST Analysis
- 4.3 Experts Opinion
- 5. MEA Influenza Vaccines Market Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Increase in Government Support to Promote Influenza Vaccination
- 5.2 Market Restraints
- 5.2.1 High Cost of Vaccine Development
- 5.3 Market Opportunities
- 5.3.1 Emerging Economies
- 5.4 Future Trends
- 5.4.1 Strong Pipeline Candidates for Influenza Vaccines
- 5.5 Impact Analysis
- 6. Influenza Vaccine Market MEA Analysis
- 6.1 MEA Influenza Vaccines Market Revenue Forecasts And Analysis
- 7. MEA Influenza Vaccines Market- By Vaccine Type
- 7.1 Overview
- 7.2 MEA Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
- 7.3 Quadrivalent Vaccines
- 7.3.1 Overview
- 7.3.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.4 Trivalent Vaccines
- 7.4.1 Overview
- 7.4.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 8. MEA Influenza Vaccines Market- By Virus Type
- 8.1 Overview
- 8.2 MEA Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
- 8.3 Influenza Virus Type A
- 8.3.1 Overview
- 8.3.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)

Scotts International, EU Vat number: PL 6772247784

- 8.4 Influenza Virus Type B
- 8.4.1 Overview
- 8.4.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 9. MEA Influenza Vaccines Market By Technology
- 9.1 Overview
- 9.2 MEA Influenza Vaccines Market, By Technology 2022 & 2028 (%)
- 9.3 Egg-Based
- 9.3.1 Overview
- 9.3.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 9.4 Cell-Based
- 9.4.1 Overview
- 9.4.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 10. MEA Influenza Vaccines Market- By Route of Administration
- 10.1 Overview
- 10.2 MEA Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
- 10.3 Injection
- 10.3.1 Overview
- 10.3.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 10.4 Nasal Spray
- 10.4.1 Overview
- 10.4.2 MEA Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 11. MEA Influenza Vaccines Market Country Analysis
- 11.1 MEA Influenza Vaccine Market Revenue and Forecasts To 2028
- 11.1.1 Overview
- 11.1.2 MEA: Influenza Vaccine Market, by Country, 2022 & 2028 (%)
- 11.1.2.1 Saudi Arabia: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.1.1 Saudi Arabia: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.1.2 Saudi Arabia: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
- 11.1.2.1.3 Saudi Arabia: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
- 11.1.2.1.4 Saudi Arabia Influenza Vaccine Market, by Technology Revenue and Forecast to 2028 (USD Million)
- 11.1.2.1.5 Saudi Arabia Influenza Vaccine Market, by Route of Administration Revenue and Forecast to 2028 (USD Million)
- 11.1.2.2 UAE: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.2.1 UAE: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.2.2 UAE: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
- 11.1.2.2.3 UAE: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
- 11.1.2.2.4 UAE Influenza Vaccine Market, by Technology Revenue and Forecast to 2028 (USD Million)
- 11.1.2.2.5 UAE Influenza Vaccine Market, by Route of Administration Revenue and Forecast to 2028 (USD Million)
- 11.1.2.3 South Africa: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.3.1 South Africa: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.3.2 South Africa: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
- 11.1.2.3.3 South Africa: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
- 11.1.2.3.4 South Africa Influenza Vaccine Market, by Technology Revenue and Forecast to 2028 (USD Million)
- 11.1.2.3.5 South Africa Influenza Vaccine Market, by Route of Administration Revenue and Forecast to 2028 (USD Million)
- 11.1.2.4 Rest of MEA: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.4.1 Rest of MEA: Influenza Vaccine Market Revenue and Forecast to 2028 (USD Million)
- 11.1.2.4.2 Rest of MEA: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
- 11.1.2.4.3 Rest of MEA: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)

- 11.1.2.4.4 Rest of MEA: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
- 11.1.2.4.5 Rest of MEA: Influenza Vaccine Market, by Route of Administration, 2019-2028 (USD Million)
- 12. MEA Influenza Vaccine Market -Industry Landscape
- 12.1 Overview
- 12.2 Inorganic Growth Strategies
- 12.2.1 Overview
- 12.3 Organic Growth Strategies
- 12.3.1 Overview
- 13. Company Profiles
- 13.1 SEQIRUS
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Sanofi
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Hualan Biological Engineering Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Mitsubishi Chemical Group Corporation
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Serum Institute of India Pvt. Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description

Scotts International. EU Vat number: PL 6772247784

- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 MYLAN N.V.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 AstraZeneca
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms



To place an Order with Scotts International:

☐ - Print this form

Middle East & Africa Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)

Market Report | 2022-10-07 | 116 pages | The Insight Partners

RDER FORM:		
elect license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
	VAT	
	Total	
	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3	
* VAT will be added	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	
	at 23% for Polish based companies, individuals and EU based companies who are unable to provide a	
** VAT will be added mail*	at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	

Scotts International. EU Vat number: PL 6772247784

2025-05-06
2025 05 06
2023-03-00